The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
Abstract
Purpose: We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma. Patients and Methods: Chemotherapy consisted of gemcitabine (750 mg/m 2) and cisplatin (30 mg/m 2) given every 2 weeks for four doses. Chemoradiation consisted of four weekly infusions of gemcitabine (400 mg/m 2) combined with radiation therapy (30 Gy in 10 fractions administered over 2 weeks) delivered 5 days per week. Patients underwent restaging 4 to 6 weeks after completion of chemoradiation and, in the absence of disease progression, were taken to surgery. Results: The study enrolled 90 patients; 79 patients (88%) completed chemo-chemoradiation. Sixty-two (78%) of 79 patients were taken to surgery and 52 (66%) of 79 underwent PD. The median overall survival of all 90 patients was 17.4 months. Median survival for the 79 patients who completed chemo-chemoradiation was 18.7 months, with a median survival of 31 months for the 52 patients who underwent PD and 10.5 months for the 27 patients who did not undergo surgical resection of their primary tumor (P < .001). Conclusion: Preoperative Gem-Cis-XRT did not improve survival beyond that achieved with preoperative gemcitabine-based chemoradiation (Gem-XRT) alone. The longer preoperative interval required more durable biliary decompression (metal stents) but was not associated with local tumor progression. The gemcitabine-based chemoradiation platform is a reasonable foundation on which to build future phase II multimodality trials for stage I/II pancreatic cancer incorporating emerging systemic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
Katz, M. H. G., Pisters, P. W. T., Evans, D. B., Sun, C. C., Lee, J. E., Fleming, J. B., Vauthey, N. J., Abdalla, E. K., Crane, C. H., Wolff, R. A., et al. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.12.020 · Cited by 827
Self-citationPreoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the Pancreas
Evans, D. B. (1992) · Archives of Surgery · doi:10.1001/archsurg.1992.01420110083017 · Cited by 771
Self-citationEvans, D. B., Varadhachary, G. R., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Wang, H., Cleary, K. R., Staerkel, G. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8634 · Cited by 731
Self-citationRaut, C. P., Tseng, J. F., Sun, C. C., Wang, H., Wolff, R. A., Crane, C. H., Hwang, R., Vauthey, J.-N., Abdalla, E. K., Lee, J. E., et al. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000259391.84304.2b · Cited by 564
Self-citationRadiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
Lawrence, T. S., Chang, E. Y., Hahn, T. M., Hertel, L. W., & Shewach, D. S. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)02134-5 · Cited by 308
Pisters, P. W. T., Wolff, R. A., Janjan, N. A., Cleary, K. R., Charnsangavej, C., Crane, C., Lenzi, R., Vauthey, J., Lee, J. E., Abbruzzese, J. L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.064 · Cited by 187
Self-citationPhilip, P. A., Zalupski, M. M., Vaitkevicius, V. K., Arlauskas, P., Chaplen, R., Heilbrun, L. K., Adsay, V. N., Weaver, D. W., & Shields, A. F. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3<569::aid-cncr1356>3.0.co;2-d · Cited by 135
Cited by
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Asbun, H., Bain, A., Behrman, S. W., Benson, A. B., Binder, E., Cardin, D. B., Cha, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0131 · Cited by 1,020
Self-citationMukherjee, S., Hurt, C. N., Bridgewater, J., Falk, S., Cummins, S., Wasan, H., Crosby, T., Jephcott, C., Roy, R., Radhakrishna, G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70021-4 · Cited by 355
Transport properties of pancreatic cancer describe gemcitabine delivery and response
Koay, E. J., Truty, M. J., Cristini, V., Thomas, R. M., Chen, R., Chatterjee, D., Kang, Y., Bhosale, P. R., Tamm, E. P., Crane, C. H., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73455 · Cited by 184
Koay, E. J., Lee, Y., Cristini, V., Lowengrub, J. S., Kang, Y., Lucas, F. A. S., Hobbs, B. P., Ye, R., Elganainy, D., Almahariq, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3668 · Cited by 110
Self-citationA 25-gene classifier predicts overall survival in resectable pancreatic cancer
Birnbaum, D. J., Finetti, P., Lopresti, A., Gilabert, M., Poizat, F., Raoul, J.-L., Delpero, J.-R., Moutardier, V., Birnbaum, D., Mamessier, E., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0936-z · Cited by 51
Metadata
- Authors
- Varadhachary, G. R., Wolff, R. A., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Abdalla, E., Wang, H., Staerkel, G. A., Lee, J. H., Ross, W. A., Tamm, E. P., Bhosale, P. R., Krishnan, S., Das, P., Ho, L., Xiong, H., Abbruzzese, J. L., & Evans, D. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-20
- Volume
- 26
- Issue
- 21
- Pages
- 3487-3495
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097421939
- Cited by
- 466
- References
- 10
- FWCI
- 15.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head. https://app.cochat.ai/papers/10.1200/jco.2007.15.8642
- The paper
- Varadhachary, G. R., Wolff, R. A., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Abdalla, E., Wang, H., Staerkel, G. A., Lee, J. H., Ross, W. A., Tamm, E. P., Bhosale, P. R., Krishnan, S., Das, P., Ho, L., Xiong, H., Abbruzzese, J. L., & Evans, D. B. (2008). Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.8642
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
